Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
this is why I have felt HIKMA may slip by I dont think Healthnet does
perhaps but no one uses fibrates or niacin anymore ... maybe a few gemfibrozil
well this data is old but
about 3.4 mil in the us with trigs >500
Treatment rate is about 18% = 900,000
There are 75K generic scripts per month - assume they are written for 3 mos meaning 300K Rx for generic per year
assume vascepa has 15% market penetration for Trigs >500 they are at 70 K per month or 10K for trigs >500 or about 40K per year
meaning current market penetration is 340K with max 900k (unless HIKMA plans to market for Trigs >500 unlikely )
but as I have said all along I dont think HIKMA is found guilty I do think Healthnet is found guilty of such
https://www.ajconline.org/article/S0002-9149(10)02418-5/pdf#:~:text=The%20distribution%20of%20TG%20levels%20in%20the%20sample%20are%20listed,to%20roughly%203.4%20million%20Americans.
Perhaps the question is -
IS the problem the intertwining or the mechanism that induces such ?
I would argue that intertwining infringes regardless of the mechanism of induction ....
The only approved indication is trigs >500 whcih is very very small compared to CAD market
Can everyone post on this site about how we think HIKMA is going to lose the case - we need to get opinion swaying for AMRN !!
https://seekingalpha.com/article/4446974-hikma-pharmaceuticals-hkmpf-ceo-sigurdur-olafsson-on-q2-2021-results-earnings-call-transcript
That quote is so blatantly self serving its hilarious ...I cnat believe he actually said that - like he's trying to convince the judges that he always does the right thing
NO but we did hit $3.xx and I bought ....
If the US market is restored ( and I know that still a big if) but assuming it is the market has already valued the stock ar $26 for that scenario
hey we need more tweets about rainbows unicorns sheroes and "we are doing a really swell job "
you could but turn docs against the med and it will have NO Market whatsoever- instead be more subtle - advertise - is your doctor on the cutting edge of information and technology ? If you have CAD or DM2 are you on vascepa to add 25% reduction in coronary events? If not ask your doctor ...
Docs will see that and immediately think - I dont want to be labelled as not knowing whats going on and they will reach for the med
believe me - they are TOTALLY unaware - there are a multitude of reason but most docs are just trying to keep their head above water - if you told one of them that they were going to get a paid year off every five like a professor's sabbatical so that they could keep up on the latest research most would fall over in disbelief - I use to teach medical students and residents but I stopped after one of them asked me if I would do it again - MY frank response - NO WAY - much easier ways to make a living
Thats exactly what we need .... too bad there isnt any research showing increase MI's with lovaza - if Stevie NIssen wants to do something useful he should start a study on that ....
Fascinating ...just talking to a guy who writes algorithms for nanosecond trading predicting what other computers will do for trading - nanosecond day traders ....
THe implications here now fall solely onto AMRN's marketing
There is absolutely NO REASON for Lovaza scripts to have better performance then Vascepa - the only possible reason is lack of informed medical practitioners
THis is like having a 1 hp motor outperform a 10 HP motor - the only possible reason is the 10 HP is not being run appropriately !!!!
Someone NEEDS TO INFORM PRACTITIONERS about the difference and its not complicated !!!
They need to quit tweewting about daisies and unicorns and do something useful !!!
just get this into the hands of every doc !!!
**************************************
Appropriate classification and positioning of Omega 3 medications.
Lovaza (L) and Generic Lovaza (gL)
These are a combinations of EPA and DHA. The only appropriate utilization is for triglycerides > 500 to prevent pancreatitis. NONE of these drugs have any outcomes study showing any improvement in Cardiovascular outcomes! The only possible use of these medications is the reduction of triglycerides > 500 for the prevention of pancreatitis. Lovaza may actually induce cardiovascular disease since it increases LDL by 49%. These medications should NOT be listed as cardiovascular medicines.
Vascepa (V) and Generic Vascepa (gV)
These medications contain only EPA – both of these medication can be utilized for Trigs >500mg/dl, however, The vast majority of prescriptions written for Vascepa are for the REDUCE IT indications (individuals with known CAD or those with Diabetes and two risk factors on statins with trigs > 150 ), meaning it is being utilized to prevent cardiovascular disease. You cannot substitute Lovaza or generic lovaza for these prescriptions - they have NO indication for this and you may actually be harming the patient by increasing their LDL by 49% - Lovaza and Vascepa are DIFFERENT medications and are NOT Interchangeable.
Furthermore if a prescription is written for Vascepa for REDUCE IT indications (95% of use) you cannot substitute generic Vascepa – this is direct patent infringement and law suits are now being filed against insurers for such ( Healthnet). Generic Vascepa is ONLY approved for trigs >500 it is NOT approved for reduction of cardiovascular risk and doing so will expose you to liability for direct patent infringement.
In summary:
Omega 3's that can be used for Trigs >500
Lovaza – Generic Lovaza - Vascepa - Generic Vascepa
Omega 3's that can bu utilized for cardiovascular risk Reduction
VASCEPA
Probably are not anxious to release a PR saying they got their butts kicked ...
when the stock takes off YEE looks like he has no repsectable capability
ahh gotta love "The Fools"
can anyone on twitter help to inform this poor soul what happened
published 2:31 8 /5 no mention of TEVA case as reason for stock price increase ..
https://www.fool.com/investing/2021/08/05/why-amarin-is-soaring-today/
Docs get sued for malpractice ... and its not fun
To us its big news to the rest of the world ... they will get around to it eventually - if I was a short player Id short TEVA right now ...
AMrn should send a letter to HIKMA / Healthnet offering to settle for quadruple damages ...
and now for the herpes jokes ...
I named my dog herpes
because he never heels
Hear about the guy who got ocular herpes ?
He was looking for love in all the wrong places
I'll let myself out .....
Biotech powerball lottery ?
AMRN Rep dropped off advertising materials at my office and wrote 'make certain you DAW Rx's." They must be recognizing that generics are eating their lunch ...
They need to add a PBM - pharmacy benefits manager. From what I recall someone researched this and found that Healthnet is also a PBM ??
DOc writes rx ---> Pharmacist fills ----> pharmacist fills dependent on Insurance company approval (formulary) ---> Insurance company formulary managed by PBM. Manufacturers supply meds to pharmacy.
AMRN has gone after Insurer and Manufacturer - they need to add PBM and larger pharmacy chain - like Walgreens etc then all players are covered
Having said that I have all along said that I dotn think HIKMA is found guilty that my money rests on the insurer -
A motion to sever is a request by either the State or the defendant asking the court to have separate jury trials on the different charges. A motion to sever can also ask the court to sever the trials of co-defendants, resulting in the defendants being tried separately rather than together
If that were the case I dont think Thero would have stepped down ..
THe "french" spoke in kabek is equivalent to a 16th century dialect - they cant even understand one another ...lol
Thanks Capn !!
Manana.... an ethos of sloth and apathy
My biggest concern is that docs are well versed with sglt meds they view them as a "real" med and the mental link / reaction of
diabetes + heart disease needs prevention will automatically go to sglt's instead of vascepa -
The only way to prevent that is quick efficient effective marketing ... uggh ... I feel like we are sending the keystone cops up against a Navy Seal team ...
yes and its a direct competitor for Vascepa being marketed by people who know what they are doing ...
SO will BIden limit travel from CHina to the US ? But if he does that makes him a racist according to the media
Good message Patient just told me his copay for Vascepa dropped dramatically !!
Its multifactorial I have patients who have never smoked ldl is naturally under 100 low weight exercise no htn no diabetes and they have heart attacks -
Profit confirmed bought at $3.95
Dont recall if this was posted or not
https://www.medpagetoday.com/cardiology/prevention/93793
Bought at 3.95 now 4.26 - 8.6% gain in several days - should I sell KIWI ?
Dang I am not usually a short trader ....
Nice summary ... indirect rebuke of Nissen